Max Marchione consistently uses the success of GLP-1 agonists (e.g., Ozempic) to counter the claim that peptides are an inferior drug class. By highlighting that perhaps the most impactful drug of the modern era is a peptide, he argues that the entire category holds immense, untapped potential that cannot be dismissed.

Many peptides are unlikely to ever receive FDA approval because their simple, easily replicated structures make them commodities. Pharma companies won't fund billion-dollar trials for drugs they can't patent, leaving them in a permanent gray market.

Martin Shkreli claims that from a pharmaceutical development perspective, peptides are often avoided. They possess inherent weaknesses, being more complex than small molecules but less effective than large molecules like antibodies. This makes their recent popularity in biohacking circles ironic to industry insiders.

While GLP-1 has been a known target for a long time, the recent explosion in peptide therapeutics was primarily enabled by solving the historical challenge of poor half-life and exposure. Achieving one- or two-week half-lives through techniques like fatty acid acylation was the critical technological unlock for the field.

The critique of the peptide trend often misses that users aren't taking unknown chemicals. Many use compounds like Retatrutide, which is already in Phase 3 clinical trials by Eli Lilly. They are essentially front-running the FDA approval process for drugs that already have substantial clinical backing.

Martin Shkreli dismisses the biohacking trend of using peptides. He argues that without rigorous data on pharmacokinetics—how a substance is metabolized and its half-life—one doesn't have a medicine, but a delusion. He criticizes enthusiasts for ignoring the foundational science required for any pharmaceutical.

Martin Shkreli posits that the rise of self-experimentation with peptides is fueled by psychological drivers—a desire for personal control, identity, and a fundamental distrust of established institutions like the pharmaceutical industry. This frames the trend as a cultural phenomenon, not purely a medical one.

CEO Jonathan Steckbeck simplifies a complex topic by describing peptides as a "Goldilocks modality." They sit between small molecules (good access, poor specificity) and biologics (poor access, good specificity), ideally offering the best of both worlds for targeted drug delivery.

Shkreli dismisses the peptide trend popular in tech circles. He contends that without understanding a drug's half-life (pharmacokinetics), its specific biological target, and rigorous double-blind trial data, users are engaging in delusion, not science. He criticizes the dismissal of the FDA and established pharma processes.